Valvular & structural heart disease
Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study
Authors' conclusion
The 1-year results of the TriCLASP study confirm the safety and effectiveness of T-TEER with the PASCAL system in patients with ≥severe TR. Patients experienced significant TR reduction, low mortality, high freedom from HFH, and significant improvements in symptoms, functional capacity, and quality of life.
Study context
- Population
- Patients with ≥severe tricuspid regurgitation (TR)
- Participants
- 300 enrolled patients
- Outcome
- Baseline characteristics
Main finding
As reported in the abstract
Mean age
80.1 years
Female
52.0%
≥severe TR
75.8%
Observational data: associations, not effects.
Further findings
TR reduced to ≤moderate · 1 year
- Patients with TR reduced to ≤moderate
- 87.7%
- p<0.001
Survival and freedom from heart failure hospitalisation (HFH), Kaplan-Meier estimates · 1 year
- Survival
- 88.3±1.9%
- Freedom from HFH
- 83.2±2.3%
Annualised HFH rates, 12 months pre- versus post-procedure
- Decrease in annualised HFH rates
- 72.2%
- p<0.001
Functional and quality-of-life outcomes, baseline to 1 year
- Patients in New York Heart Association Class I/II
- 74.5%
- Increase in 6-minute walk distance
- 29.4-metre
- Increase in Kansas City Cardiomyopathy Questionnaire score
- 8.3-point
- p<0.001
Safety
Composite major adverse events (MAE) · 30 days and 1 year
- MAE rate at 30 days
- 1.7%
- MAE rate at 1 year
- 12.7%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →